A5050170381- Cardiac Valve Diseases and Treatments
- Cardiac Imaging and Diagnostics
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Mechanical Circulatory Support Devices
- Cardiovascular Disease and Adiposity
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Infective Endocarditis Diagnosis and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Peripheral Artery Disease Management
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiac Health and Mental Health
- Cardiac Arrest and Resuscitation
- Cardiac pacing and defibrillation studies
- Vascular Procedures and Complications
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Cerebrovascular and Carotid Artery Diseases
- Aortic aneurysm repair treatments
- Hemodynamic Monitoring and Therapy
- Venous Thromboembolism Diagnosis and Management
- Cancer Treatment and Pharmacology
- Atherosclerosis and Cardiovascular Diseases
MedStar Washington Hospital Center
2023-2025
MedStar Georgetown University Hospital
2024-2025
Georgetown University
2024-2025
MedStar Health
2024
Washington Hospital
2024
University of Missouri
2020-2022
University of Missouri Hospital
2021-2022
Houston Methodist
2019-2021
Methodist Hospital
2019-2021
Harry S. Truman Memorial Veterans' Hospital
2021
The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an increased risk major adverse cardiovascular events (MACE) compared non-ICI therapies in patients lung cancer. ICIs activate the host system target cancer cells. Though uncommon, immune-related can be life-threatening. A retrospective single-institution cohort 252 pathologically confirmed who received ICI or therapy analyzed. primary endpoint MACE, defined as a composite death,...
Background Coronary microvascular dysfunction (CMD), which mimics symptoms of obstructive coronary artery disease, has significant prognostic implications. While epicardial adipose tissue normally a protective role, increased is associated with inflammation and may contribute to CMD. However, direct correlation remains unclear. We aimed investigate this association. Methods Results The CMDR (Coronary Microvascular Disease Registry) prospective, 2‐center registry that enrolling patients...
ABSTRACT Background Cangrelor is an intravenous P2Y12 receptor antagonist that exerts rapid and potent antiplatelet effects. It associated with a reduction in the indcidence of ischemic events patients acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Aims The aim our study was to investigate racial disparities their impact on outcomes among ACS who were treated cangrelor during PCI. Methods We reviewed data PCI at center from 2018 2023 divided between African...
Abstract Background Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) patients receiving anthracyclines, but knowledge regarding the clinical utility baseline at low-risk limited. Objectives The purpose this study was to investigate whether echocardiographic assessment global longitudinal strain (GLS) before treatment with anthracyclines...
ABSTRACT Background Intravascular ultrasound (IVUS) is essential for assessing complex coronary lesions, but remains underutilized in part due to difficulties image interpretation. The AVVIGO IVUS Automated Lesion Assessment (ALA) software, which uses machine learning (ML) automatic segmentation, promises simplify lesion assessment. This study evaluated the agreement stent size selection between ALA, an independent core laboratory (CL), and expert interventional cardiologist (IC) lesions....